

Drug Safety

Safety Communication Tools and Healthcare Professionals' Awareness of Specific Drug Safety Issues in Europe: A Survey Study

Sieta T. de Vries, PhD; Maartje J.M. van der Sar, MSc; Anna Marie Coleman; Yvette Escudero; Alfonso Rodríguez Pascual; Miguel-Ángel Maciá Martínez; Amelia Cupelli; Ilaria Baldelli; Ivana Šipić; Adriana Andrić; Line Michan, PhD; Petra Denig, PhD; Peter G.M. Mol, PhD; on behalf of SCOPE work package 6

Corresponding author:

P.G.M. Mol, PhD

Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands


Dutch Medicines Evaluation Board, Utrecht, The Netherlands

✉ p.g.m.mol@umcg.nl


Supplemental Digital Content

This Supplemental Digital Content contains the appendix referred to in the full version of this article, which can be found at <http://adisonline.com/drugsafety>

Electronic Supplementary Material 3. Sources through which the responders were aware of the four safety issues (i.e. combined hormonal contraceptives, diclofenac, valproate and ivabradine). **A)** Per profession; **B)** Per country¹. ¹ The ivabradine safety issue was not assessed in Norway.



A)



B)